#256
|
|||
|
|||
âñòðå÷íûé âîïðîñ - ïî÷åìó áîëüíàÿ ïîëó÷àåò íåäèãèäðîïèðèäèíîâûé àíòàãîíèñò êàëüöèÿ, à íå áåòà-áëîêàòîð? åñòü ïðîòèâîïîêàçàíèÿ?
íà îñíîâàíèè ÷åãî óñòàíîâëåí äèàãíîç ïåðâè÷íîé ëåãî÷íîé ãèïåðòåíçèè - íåò ëè äðóãèõ ïðè÷èí ñåðäå÷íîé íåäîñòàòî÷íîñòè? ÷òî ñ ÔÂ, ëîêàëüíîé êèíåòèêîé? íåò ëè ïî÷å÷íîé íåäîñòàòî÷íîñòè? ñîï.çàáîëåâàíèé? |
#257
|
||||
|
||||
Öèòàòà:
Öèòàòà:
Âàçàïðîñòàí - ýòî ïðîñòàãëàíäèí E2, à íå ïðîñòàöèêëèí (ïðîñòàãëàíäèí I2), êîòîðûé èñïîëüçóþò ïðè IPAH. Ýòî ðàçíûå ïðåïàðàòû. Ïî÷åìó åãî ïûòàþòñÿ èñïîëüçîâàòü â ÐÔ - äëÿ ìåíÿ çàãàäêà. Òðàêëèð ÿ òàê ïîíèìàþ âàðèàíòîâ ïðèîáðåñòè íåò? Ìîæåò êàêèå êâîòû èëè åùå ÷òî ñóùåñòâóþò ó âàñ òàì íà ìåñòíîì óðîâíå? |
#258
|
|||
|
|||
Öèòàòà:
Åñëè ýòî òàêè ÏËÃ, òî: 1. Íåîáõîäèìî îòìåíèòü ëþáûå àíòàãîíèñòû êàëüöèÿ, ò.ê. ïàöèåíòêà non-responder. Íàçíà÷åíèå àíòàãîíèñòîâ ïðè îòñóòñòâèè ðåçåðâà ëåãî÷íîé âàçîäèëàòàöèè ïðèâåäåò ê äàëüíåéøåìó ïàäåíèþ ñèñòåìíîãî ÀÄ è êîëëàïñó (â ëèòåðàòóðå îïèñàíû ñìåðòåëüíûå èñõîäû). 2. Âàôàðèí íóæíî îñòàâèòü, ýòî îäèí èç äâóõ ïðåïàðàòîâ, êîòîðûå ñïîñîáíû ïðîäëèòü ýòîé ïàöèåíòêå æèçíü (ó non-responders ïðîäëåâàþò æèçíü âàðôàðèí è ïðîñòàöèêëèí). 3. Íåîáõîäèìî ñêîððåêòèðîâàòü ñèìïòîìàòè÷åñêóþ òåðàïèþ ìî÷åãîííûìè (óáðàòü âîäó ïî âîçìîæíîñòè) 4. Äèãîêñèí ìîæíî îñòîðîæíî îñòàâèòü. 5. èÀÏÔ íå äàâàòü (!) 6. Âàçàïðîñòàí íå íóæåí, ýòî íå ïðîñòàöèêëèí è ýôôåêò åãî íà ëåãî÷íóþ ãåìîäèíàìèêó íå äîêàçàí. Ïðîñòàöèêëèí â Ðîññèè íå äîñòóïåí (1 ãîä ïîñòîÿííîé èíôóçèè ÷åðåç ïîìïó â Àíãëèè ñòîèò îêîëî 40 000 ôóíòîâ) 7. Ñ ñèëäåíàôèëîì ïîêà íå âñå ïîíÿòíî. Áîëåå ìåíåå ïîíÿòíî, ÷òî îí áåçîïàñåí ïðè ÕÑÍ I-II, âîçìîæíî - III. Ó Âàøåé ïàöèåíòêè - IV. Ëó÷øå áû ïîäáèðàòü òåðàïèþ ñèëäåíàôèëîì òàêîé ïàöèåíòêå â ñòàöèîíàðå, ãäå åñòü îïûò ëå÷åíèÿ ÏËÃ. |
#259
|
|||
|
|||
Öèòàòà:
"çàñòîéíûå èçìåíåíèÿ" íå âûðàæåíû, íàëè÷èå òàêèõ èçìåíåíèé íà ðåíòãåíå ñòàâèò ïîä ñîìíåíèå äèàãíîç? Âûøå ñïðàøèâàëè, ïðîâîäèëàñü ëè ïðîáà ñ âàçîäèëàòàòîðàìè, íà ðóêàõ ó ìåíÿ âûïèñêà, óïîìèíàíèÿ î òàêîé ïðîáå íåò, èç ïðîâîäèìûõ èññëåäîâàíèé: ÊÒ è àíãèîïóëüìîíîãðàôèÿ. ÊÒ (îò ÿíâàðÿ 2011ã) Çàêë.: ïðèçíàêè ëåãî÷íîé ãèïåðòåíçèè, çàñòîéíûõ ÿâëåíèé. Øàðîâèäíîå îáðàçîâàíèå ñðåäíåé äîëè ïðàâîãî ëåãêîãî. Ïðàâîñòîðîíèèé ãèäðîòîðàêñ. Ãèäðîïåðèêàðä. Àñöèò. Àíãèîïóëüìîíîãðàôèÿ ïðîâîäèëàñü â ïðîøëîì ãîäó (îáñëåäîâàëàñü ñ ïîäîçðíìåí íà ÒÝËÀ), óáåäèòåëüíûõ äàííûõ çà ÒÝËÀ íå âûÿâëåíî. Ïî ïîâîäó îáðàçîâàíèÿ â ëåãêîì, êîíñóëüòèðîâàëàñü îíêîëîãîì, îíêîïàòîëîãèÿ èñêëþ÷åíà. Êàê ÿ ïîíèìàþ ÄÇ: ÏËà ýòî äèàãíîç èñêëþ÷åíèÿ, êîãäà êàêèå-ëèáî äðóãèå ïðè÷èíû íå íàéäåíû. ( ñ øàðîâèäíûì îáðàçîàíèåì ÷òî-òî êàê òî íå ðàçîáðàëèñü òàì:àõ Äîïîëíèòåëüíî âûÿñíèëà ó ïàöèåíòêè, ÷òî â ïðîøëîì ãîäó åé àìáóëàòîðíî ðåêîìåíäîâàëè ñèëäåíàôèë, ïàöèåíòêà ñàìîñòîÿòåëüíî îòìåíèëà ïðèåì èç -çà ïîÿâëåíèÿ îòå÷íîñòè ãóá è ïàðàîðáèòàëüíîé êëåò÷àòêè, îòìå÷àëà, ÷òî "åëå âîðî÷àëà ÿçûêîì" (îòåê?). Ñèìïòîìû ïðîøëè ñàìòîÿòåëüíî. Òàê, ÷òî íå çíàþ äàæå ÷òî äåëàòü, çíà÷èò îòìåíÿþ ÀÊÊ è ïðîâîæó ëå÷åíèå ÕÑÍ.:öîíôóñåä: Íà ñåãîäíÿøíèé äåíü ïðàêòè÷åñêè êóïèðîâàíû ïåðèôåðè÷åñêèå îòåêè, óìåíüøèëñÿ â îáúåìå æèâîò, ñàìî÷óâñòâèå íåñêîëüêî óëóøèëîñü, ÀÄ íà öèôðàõ 90-100/70 ìì.ðò.ñò. Öèòàòà:
Öèòàòà:
Ô óäîâëåòâîðèòåëüíàÿ ÝõîÊà îò ÿíâàðÿ 2011 - Ô 62 %. ÑÄËÀ 88 ìì.ðò.ñò. Äèàëàòöèÿ ñòâîëà ëåãî÷íîé àðòåðèè. ÒÍ 3-4 ñò. Äèëàòàöèÿ ïîëîñòåé ïðàâûõ îòäåëîâ ñåðäöà ( âûøå ïèñàëà,÷òî âñåõ ïîëîñòåé, ïðîøó ïðîùåíèÿ). Ëåãî÷íàÿ ãèïåðòåíçèÿ 3 ñò. Âûïîò â ïîëîñòè ïåðèêàðäà(Íà ðóêàõ ó ìåíÿ òîëüêî çàêëþ÷åíèå. ÝõîÊà îáÿçàòåëüíî ïîâòîðþ). Ìî÷åâèíà è êðåàòèíèí, êàëèé â íîðìå, äèóðåç íà ôîíå ñòèìóëÿöèè "ïîëîæèòåëüíûé". Åñòü ãèïåðáèëèðóáèíåìèÿ, ÷òî ðàñöåíåíî ìíîé êàê ïðîÿâëåíèå êàðäèàëüíîãî ôèáðîçà ïå÷åíè. ÀÑÒ è ÀËÒ âåðõíÿÿ ãðàíèöà íîðìû. Îáñëåäóåòñÿ. Ñïàñèáî âñåì. Êîãäà íà÷àëà ÷èòàòü ïðî ÏËà â èíòåðíåòå åùå áîëüøå çàïóòàëàñü.:àè: |
#260
|
|||
|
|||
|
#261
|
||||
|
||||
Óâàæàåìûå êîëëåãè, êàê ïðàâèëüíî ïåðåâåñòè áîëüíîãî ñ äâóõíåäåëüíûì îïûòîì ïðèåìà êëîïèäîãðåëà íà òèêëèä? Ñïàñèáî.
|
#262
|
|||
|
|||
À ó ìåíÿ òîæå âîïðîñ, õîòÿ, ìîæåò áûòü, è íåñêîëüêî íàèâíî çâó÷àùèé äëÿ áîëåå îïûòíûõ êîëëåã. Âðîäå áû âî âñåõ ãàéäàõ ïî ëå÷åíèþ ÑÍ åñòü ðåêîìåíäàöèè ïî ñîêðàùåíèþ ïîòðåáëåíèÿ ñîëè (ñóùåñòâåííî ìåíüøå ñðåäíåñòàòèñòè÷åñêèõ 10 - 12 ãð. ñîëè â ñóòêè). Íî âîò óæå íå â 1 ðàç ïîÿâëÿåòñÿ èíôîðìàöèÿ î íåáëàãîïðèÿòíîì âëèÿíèè íà ñìåðòíîñòü ïðè îãðàíè÷åíèè ïîòðåáëåíèÿ ñîëè ó ïàöèåíòîâ ñ ÑÍ. Íàïðèìåð [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] ïî "íàâîäêå" îò óâàæàåìîãî Chevychelov. Ó ìåíÿ îò ýòîãî íåêèé êàê ãîâîðèòñÿ "êîãíèòèâíûé äèññîíàíñ". Ïðåäïîëîæèòü ìîãó òîëüêî òî, ÷òî íà òåðàïèè äèóðåòèêàìè çàñòîéíîé ÑÍ æåñòêîå îãðàíè÷åíèå ïîòðåáëåíèÿ ñîëè óâåëè÷èâàåò ÷àñòîòó ãèïîíàòðèåìèè, çíà÷èìîé ãèïîòîíèè, ÷òî ìîæåò ïðèâåñòè ê îñòðîé èøåìèè ìîçãà/ìèîêàðäà..
|
#263
|
||||
|
||||
×òî êóïèë, òî ïðîäàë. Äà è ñàì îáçîð íå ìåíÿåò êëèíè÷åñêèå ïðèîðèòåòû.
Conclusions Despite collating more event data than previous systematic reviews of RCTs (665 deaths in some 6,250 participants) there is still insufficient power to exclude clinically important effects of reduced dietary salt on mortality or CVD morbidity. Our estimates of benefits from dietary salt restriction are consistent with the predicted small effects on clinical events attributable to the small BP reduction achieved. Ìîæåò áûòü áîëåå îïûòíûå êîëëåãè ìåíÿ íå ïîääåðæàò, íî â ñâîåé ðàáîòå ÿ ïðèäåðæèâàþñü òîëüêî òåõ ðåêîìåíäàöèé, êîòîðûå åñòü â ò.í. ïåðâè÷íûõ ãàéäàõ, íàïðèìåð, ÷òî êàñàåòñÿ ÑÍ [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Òðàéëû, îáçîðû è ìåòà-àíàëèçû (ñ ìîåé, âïîëíå âîçìîæíî îøèáî÷íîé, òî÷êè çðåíèÿ) ìîãóò ïðèíèìàòüñÿ âî âíèìàíèå, íî êëèíè÷åñêîå ðåøåíèå ïðèíèìàåòñÿ òîëüêî ïî ãàéäàì. |
#264
|
||||
|
||||
Öèòàòà:
PS Êñòàòè, ñ òèêëèäîì â Ìîñêâå íàïðÿæåíêà. |
#265
|
||||
|
||||
Ì. á. àëëåðãèÿ íà ïëàâèêñ? Ìíå òîëüêî ýòî â ãîëîâó ïðèõîäèò ...
Íàâåðíîå, íàäî â îäèí ïðåêðàñíûé äåíü âûïèòü âìåñòî òàáëåòêè ïëàâèêñà òèêëèä. |
#266
|
|||
|
|||
Öèòàòà:
Öèòàòà:
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Ñ óâàæåíèåì |
#267
|
|||
|
|||
Öèòàòà:
|
#268
|
|||
|
|||
Öèòàòà:
|
#269
|
|||
|
|||
Öèòàòà:
|
#270
|
|||
|
|||
åùå, íà âñÿêèé ñëó÷àé [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Clopidogrel Desensitization After Drug-Eluting Stent Placement Karl F. von Tiehl, MD,* Matthew J. Price, MD, FACC,† Rafael Valencia, MD,† Katherine J. Ludington, MD, FACC,‡ Paul S. Teirstein, MD, FACC,† Ronald A. Simon, MD* Objectives We hypothesized that a standardized outpatient clopidogrel desensitization protocol would be safe and effective. Background Adverse reactions to clopidogrel are not uncommon, and affected patients must switch to ticlopidine after drugeluting stent placement, despite its more malignant side-effect profile, because of the risk of ischemic events associated with premature discontinuation of dual antiplatelet therapy. Methods Patients with suspected clopidogrel sensitivity were treated with escalating doses of clopidogrel administered orally in solution until either a clinically significant reaction occurred or the full 75-mg tablet of clopidogrel was tolerated. Desensitization was performed on an outpatient basis except in cases in which the subjects were inpatients at the time of enrollment. Follow-up was performed at 2 to 4 weeks and 6 months after treatment. Successful desensitization was defined as the ability to take clopidogrel 75 mg daily without a mucocutaneous, bronchial, or anaphylactic response. Results We enrolled 24 consecutive patients with suspected reactions to clopidogrel after DES implantation, 20 of whom were outpatients. During desensitization, allergic-type reactions occurred in 4 patients and angina occurred in 1 patient. Desensitization was acutely successful in all 24patients, and by 6-month follow-up, 1 patient had persistent but improved pruritus controlled with oral antihistamines and 23 remained asymptomatic, with only 2 patients requiring repeat desensitization. Conclusions Clopidogrel desensitization is safe and effective, induces a sustained remission, and could be advantageous in treating outpatients who are at-risk for premature discontinuation of dual antiplatelet therapy. (J Am Coll Cardiol 2007;50:2039–43) [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Ñ óâàæåíèåì |